Naoto Tada Ueno, MD, PhD, FACP
Clinician + Researcher
- Professor of Medicine, Nylene Eckles Distinguished Professor in Breast Cancer Research
- Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Research Program and Clinic
- Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Department of Breast Medical Oncology
- The University of Texas MD Anderson Cancer Center
- 1515 Holcombe Boulevard, Unit 1354
- Houston, Texas, 77030
- Phone: 713.792.8754
- Fax: 888.375.2139
Research and Clinical Interests
I have a strong background in translational breast cancer research in the areas of cancer biology and molecular therapeutics, with specific training and expertise in the key research areas of EGFR/ERK/JNK/TGF-beta signaling and in vivo modeling. I also trained as a breast medical oncologist at MD Anderson and simultaneously learned how to conduct early drug clinical research development related to breast cancer. I am now a practicing physician-scientist who has experience in conducting both targeted and immunotherapy in Phase I/II setting.
Since becoming a faculty member at MD Anderson, I have expanded my research to include the EGFR/ERK pathway in both breast and ovarian cancer (HER2, JNK, TIG1, FOXO3, epigenetic, etc.). Over the past 10 years, I have successfully managed projects in breast cancer biology related to triple-negative breast cancer, inflammatory breast cancer, metastasis, cancer stem cells and drug resistance of cancer cells.
Currently I serve as an Executive Director of Morgan Welch Inflammatory Breast Cancer (MWIBC) Research Program and Clinic and Section of Translational Breast Cancer Research (TBCR). MD Anderson MWIBC is the world’s largest IBC-specific research program that conducts IBC-specific clinical trials, understanding the aggressiveness of cancers by studying cancer stem cells and the impact of microenvironment (inflammation and immunological effect).
- Advanced Molecular Diagnostics (Circulating Tumor Cells)
- Cancer Microenvironment
- HER2/EGFR/JNK/TGF-beta Signaling
- Inflammatory Breast Cancer
- Metastatic Breast Cancer
Education and Board Certifications
Wakayama Medical College, Wakayama, Japan (1989)
Montefiore University Hospital, University of Pittsburgh, Pittsburgh, PA, Internal Medicine (1991)
University of Pittsburgh Medical Center, Pittsburgh, PA, Internal Medicine (1993)
University of Texas MD Anderson Cancer Center, Houston, TX, Medical Oncology and Blood and Marrow Transplantation (1996)
American Board of Internal Medicine – Medical Oncology American Board of Internal Medicine – Internal Medicine
Years in Practice
Affiliations and Memberships
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis Breast Cancer Research and Treatment; 2015 EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer Oncotarget; 2017 Thrombocytosis as a prognostic factor in inflammatory breast cancer Breast Cancer Research and Treatment; 2017 Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system The Lancet Oncology; 2017 Total of 99 publications as of November 5, 2017
2016-0177: A randomized phase II study of neoadjuvant carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen for newly diagnosed primary triple-negative inflammatory breast cancer 2016-0096: A phase II study of anti-PD-1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy 2016-0890: A phase II study of triple combination of Atezolizumab cobimetinib + eribulin (ACE) in patients with chemotherapy resistant metastatic inflammatory breast cancer 2014-0533: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (IBC) or non-IBC triple negative breast cancer (TNBC) who have achieved clinical response or stable disease to prior chemotherapy
Affiliated IBC-IC Center(s)
Become part of our international consortium of researchers, clinicians, advocates and centers worldwide dedicated to ending IBC.Join >
IBCIC.org makes every effort to keep researcher information as up-to-date as possible.
Contact this researcher to confirm any information regarding his or her profile.